• Economy
  • Politics
  • Society
  • Securities
  • Real estate
  • Culture
  • Entertainment
  • Sports
  • Opinion
Economy Corporation Pharma & Bio
Society Politics IT·Science
Securities Real Estate Global
Opinion Entertainment Sports Culture
Video Auto in Golf in
PHARM EDAILY Market in TheBeLT
Securities
Stock Reports

DOOSAN ENERBILITY Confirms Steady Growth in Order Intake... Target Price Lowered—IBK

IBK Investment & Securities announced on the 28th that it is maintaining its “Buy” investment rating for DOOSAN ENERBILITY(034020), citing continued robust growth in new orders. However, the target pr…
  • 2026-07-28 08:04:45
  • kyoungeun kim
Stock Reports

Naver Allays Concerns Over AI Factory Funding… Stock Price Headed for 330,000 Won—KB

On the 28th, KB Securities maintained its “Buy” rating and target price of 330,000 won for NAVER(035420)(Naver), stating that concerns regarding funding for its artificial intelligence (AI) factory bu…
  • 2026-07-28 07:55:34
  • Kim Kyung-eun
Stock Reports

DOOSAN: 'Buy' in Undervalued Territory Given the Value of Its Core Businesses—NH

NH INVESTMENT & SECURITIES announced on the 28th that it is maintaining its “Buy” investment rating and target price of 2 million won for DOOSAN(000150). Lee Seung-young, an analyst at NH INVES…
  • 2026-07-28 07:53:17
  • Kwon Oh Seok
Research

"KOSPI Opens Lower as Semiconductor Market Uncertainty Persists Despite Easing U.S.-Iran Tensions"

Analysts predict that market indices will come under pressure as downward pressure stemming from Chinese semiconductors comes to the fore, even as macroeconomic headwinds have eased due to falling oil…
  • 2026-07-28 07:52:17
  • kyoungeun kim
Issues & Trends

DOOSAN ENERBILITY: Expectations for U.S. Investments and Nuclear Power Plant Contracts—Shinhan

Shinhan Investment Securities projected that DOOSAN ENERBILITY(034020)will continue its medium- to long-term growth momentum, citing a series of major developments—including U.S. investments, the Viet…
  • 2026-07-28 07:51:26
  • Kim Hyung-il
Stock Reports

LG Innotek’s Target Price Lowered to 1 Million Won… “Earnings Growth Remains Solid”—NH

On the 28th, NH INVESTMENT & SECURITIES lowered its target price for LG Innotek(011070)from 1.2 million won to 1 million won, a 16.7% reduction. This move reflects the recent decline in valuations amo…
  • 2026-07-28 07:43:20
  • Kim Kyung-eun
Stock Reports

SKC Narrows Loss on Improved Chemicals Business… But Return to Profit Still a Way Off—Samsung

SamsungSecurities assessed that SKC(011790)narrowed its loss in the second quarter thanks to improved profitability in its chemicals business, but noted that it will take more time to return to an ove…
  • 2026-07-28 07:40:39
  • KIM YOON-JEONG
Disclosure Plus

WAVUS Wins Contract to Build 'Elevating Vertiport Platform' for KoreaAirportService

WAVUS(336060), a company specializing in geographic information systems (GIS) and digital twins, announced on the 27th that it has been awarded the “Elevating Digital Vertiport Platform Construction P…
  • 2026-07-27 20:56:02
  • Kwon so hyun
Disclosure Plus

Kolon TissueGene, Inc. Executives, Including CEO Jeon Seung-ho, Make First Joint Purchase of Company Stock Since Inbosa Phase 3 Trial Failure

Kolon TissueGene, Inc.(950160) executives have jointly purchased company stock for the first time since the failure of the TG-C U.S. Phase 3 clinical trial. Jeon Seung-ho, co-CEO of Kolon TissueGen…
  • 2026-07-27 19:37:02
  • NA EUN-KYUNG
Disclosure Plus

CHONGKUNDANG Receives Approval for Phase 3 Clinical Trials in Korea for New Hypertension Drug 'CKD-339'

CHONGKUNDANG(185750)’s hypertension treatment candidate “CKD-339,” currently under development, is set to enter Phase 3 clinical trials in South Korea.CHONGKUNDANG HOLDINGS CORP. announced on the 27th…
  • 2026-07-27 19:29:02
  • NA EUN-KYUNG
prev 71 72 73 74 75 76 77 78 79 80 next

PHARM EDAILY

Shorts

EDAILY
  • 92, Tongil-ro, Jung-gu, Seoul, Korea
  • +82 2 3772 0114
  • webmaster@edaily.co.kr

※ This article has been translated using AI technology for the convenience of readers.

EDAILY provides this translation on an “as is” basis and makes no warranties, express or implied, regarding its accuracy, reliability, completeness, merchantability, or fitness for a particular purpose.
Due to the limitations of machine translation, the translated content may differ from the original Korean article. In the event of any discrepancy, the original Korean version shall prevail.
EDAILY shall not be liable for any loss or damage arising from the use of, or reliance on, the translated content.

© 2026 Copyrights by edaily. All Rights Reserved.
Korea
English